OSR Holdings agreed to purchase proprietary immunotherapy technology and VXM01 pipeline assets from Swiss affiliate Vaximm AG effective May 27, 2026. The transaction restructures intra-group intellectual property ownership to optimize tax treatment, with payment contingent on future milestone triggers under an existing license agreement.